Shopping Cart
- Remove All
Your shopping cart is currently empty
GDC-0834
😃Good
Catalog No. T11379Cas No. 1133432-49-1
GDC-0834 is a potent and selective BTK inhibit that inhibits BTK with an in vitro IC50 of 5.9 nM (biochemical assays) and 6.4 nM (cellular assays), and with an in vivo IC50 of 1.1 μM (mouse) and 5.6 μM (rat).
GDC-0834
😃Good
Catalog No. T11379Cas No. 1133432-49-1
GDC-0834 is a potent and selective BTK inhibit that inhibits BTK with an in vitro IC50 of 5.9 nM (biochemical assays) and 6.4 nM (cellular assays), and with an in vivo IC50 of 1.1 μM (mouse) and 5.6 μM (rat).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $198 | 7-10 days | |
| 5 mg | $399 | 7-10 days | |
| 1 mL x 10 mM (in DMSO) | $546 | 7-10 days |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "GDC-0834"
Ibrutinib
Cited
PCI-32765
T1835936563-96-1
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
- $36
Size
QTY
CitedOrelabrutinib
ICP-022
T123171655504-04-3
Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
- $83
Size
QTY
(±)-Zanubrutinib
(±)-BGB-3111
TQ00391633350-06-7
(±)-Zanubrutinib ((±)-BGB-3111) is a potent, orally available Bruton's tyrosine kinase (Btk) inhibitor, exhibiting superior oral bioavailability, higher exposure, and more complete target inhibition.
- $42
Size
QTY
JAK3/BTK-IN-1
T98142674036-91-8In house
JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases. JAK3/ BTk-in-1 simultaneously inhibited the BTK/JAK3 signaling pathway, showing a synergistic effect. JAK3/ BTK-in-1 is a potential compound for the treatment of immune-related diseases, such as autoimmune diseases, certain types of cancer (including lymphoma and leukemia), and other diseases that may be characterized by an unbalanced immune response.
- $247
Size
QTY
CP-547632
T10870L252003-65-9In house
CP-547632 is an orally available and potent, ATP-competitive dual inhibitor of VEGFR-2 and FGF kinase F with IC50s of 11 nM and 9 nM, respectively. CP-547632 is selective, with higher selectivity for VEGFR2 and bFGF than for EGFR, PDGFRβ and related tyrosine kinases (TKs). PDGFRβ and related tyrosine kinases (TKs) CP-547632 has antitumour activity.
- $30
Size
QTY
Atuzabrutinib
SAR 444727, PRN473
T390561581714-49-9
Atuzabrutinib (SAR 444727) is a selective Bruton's tyrosine kinase (Btk) inhibitor that inhibits intra-neutrophilic neutrophilic granulocytes through inhibition of the adhesion receptor signaling pathway, and can be used to study autoimmune disorders such as arthritis in rheumatoid rodents and pemphigus vulgaris.
- $189
Size
QTY
evobrutinib
MSC2364447C, M2951
T43871415823-73-2
Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the development and functioning of various immune cells including B -lymphocytes and macrophages. PreClinical research suggests it may be therapeutically useful in certain autoimmune diseases.
- $35
Size
QTY
BMS-986142
T51381643368-58-4
BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).
- $143
Size
QTY
CGI-1746
T2472910232-84-7
CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
- $34
Size
QTY
Edralbrutinib
TG-1701
T632721858206-58-2In house
Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity used in treating tumors, immune system disorders, and blood and lymphatic system disorders. Additionally, Edralbrutinib is studied for its efficacy in membranous glomerulonephritis and optic neuromyelitis optica.
- $197
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | GDC-0834 is a potent and selective BTK inhibit that inhibits BTK with an in vitro IC50 of 5.9 nM (biochemical assays) and 6.4 nM (cellular assays), and with an in vivo IC50 of 1.1 μM (mouse) and 5.6 μM (rat). |
| Targets&IC50 | BTK:5.9 nM |
| In vitro | GDC-0834 is shown to be a potent reversible inhibitor of six known aldehyde oxidase (AO) substrates with IC50 values ranging from 0.86 to 1.87 μM.?GDC-0834 suppresses BTK kinase activity with an IC50 value of 5.9±1.1 nM with Hill slope value of ?0.84±0.07 (mean±S.E.). |
| In vivo | In a rat collagen-induced arthritis (CIA) study, GDC-0834 exhibits a dose-dependent inhibition of phosphorylated Bruton's tyrosine kinase (pBTK-Tyr223) in rat blood. The estimated half-maximal inhibitory concentration (IC50) for pBTK-Tyr223 inhibition in rats is 5.6±1.6 μM, demonstrating a moderate potency with a mean (m) value of 0.51±0.087. Furthermore, treatment with GDC-0834 in BALB/c mice demonstrates dose-dependent suppression of pBTK-Tyr223, with dosages of 150 or 100 mg/kg achieving nearly complete inhibition (97% and 96%, respectively) of pBTK-Tyr223 levels in the blood after 2 hours. |
| Molecular Weight | 596.74 |
| Formula | C33H36N6O3S |
| Cas No. | 1133432-49-1 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 32 mg/mL (53.62 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy GDC-0834 | purchase GDC-0834 | GDC-0834 cost | order GDC-0834 | GDC-0834 chemical structure | GDC-0834 in vivo | GDC-0834 in vitro | GDC-0834 formula | GDC-0834 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.